Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma

The recent advent of targeted and immune-based therapies has revolutionized the treatment of melanoma and transformed outcomes for patients with metastatic disease. The majority of patients develop resistance to the current standard-of-care targeted therapy, dual BRAF and MEK inhibition, prompting e...

Descripción completa

Detalles Bibliográficos
Autores principales: Lelliott, Emily J., McArthur, Grant A., Oliaro, Jane, Sheppard, Karen E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137893/
https://www.ncbi.nlm.nih.gov/pubmed/34025662
http://dx.doi.org/10.3389/fimmu.2021.661737

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137893/
https://www.ncbi.nlm.nih.gov/pubmed/34025662
http://dx.doi.org/10.3389/fimmu.2021.661737

Ejemplares similares